Cleo Diagnostics expands ovarian cancer trial

Cleo Diagnostics Limited (ASX:COV) has announced a significant partnership with Melbourne's Royal Women's Hospital for its CLEO ovarian cancer trial. This collaboration aims to enhance patient sampling and increase market awareness for the CLEO ovarian cancer blood test, which is a key component of the company's ongoing efforts to improve early detection of ovarian cancer.

Strategic trial expansion and future goals

Cleo Diagnostics Limited's recent partnership with the Royal Women's Hospital marks an important step in its CLEO ovarian cancer trial. The trial, led by Associate Professor Orla McNally, focuses on expanding patient samples and optimizing the company's ovarian cancer blood test. The U.S. clinical trial remains pivotal, supporting a planned FDA submission in 2025. CLEO is also working on reimbursement strategies, international collaborations, and market engagement to ensure the blood test's availability. The company's leadership, including CEO Dr. Richard Allman, is steering these initiatives. The CLEO test, based on the CXCL10 biomarker, has the potential to address the unmet need for early ovarian cancer detection, thereby improving patient outcomes. The company remains cautious with forward-looking statements, acknowledging associated risks and uncertainties.

Executive commentary on new partnership

The inclusion of the Royal Women's Hospital in our trial is a critical milestone. It not only helps us expand our patient sampling but also optimizes our CLEO blood test. We are committed to advancing our U.S. clinical trial, which is crucial for our FDA submission projected for 2025.